Followers | 237 |
Posts | 10817 |
Boards Moderated | 0 |
Alias Born | 07/17/2006 |
Friday, May 22, 2020 1:25:33 PM
At issue unlike Du's conclusion that a POSA would think it obvious to use EPA to lower Triglycerides because EPA would not increase LDL levels..ACTUALLY a POSA would think it obvious that EPA (like all other trig lowering therapies) would obviously increase LDL..Since DHA, Niacin, fibrates all increased the LDL levels.
More to the point..it was well understood why Trig lowering would increase LDL-C and this was substantiated by the Friedewald Equation...
LDL = TC(total cholesterol)- HDL-C(high density lipoprotein cholesterol) -Trigs/5..
.The Friedwald Equation has proven its validity in a trial,of more than 30,000.measurements The Friedewald equation has been criticised for being inaccurate for very high trigs..But the reality is a these inaccuracies can be avoided by a simple correction of the Trigs/5 factor..
The importance of the Friedewald equation was well known before and during the MORI and KURA trials period. The simple arithmetic of this equation makes it perfectly obvious that if the TC and HDC remain constant then any lowering of the trigs must result in a higher level of LDL..And that would what would have been obvious to both Mori and Kura. So arguing a POSA would predict EPA would lower trigs and not raise LDL is factully incorrect..A POSA would think it obvious that if EPA lowers trigs it must also raise LDL..
And actually in addition to the Friedewald equation..The molecular activity which leads to the conversion of Trigs into LDL-C was understood..The Lipoprotein that transports trigs in the blood stream is VLDL..(very low density lipoprotein) and this protein is principally APO-b..Which is a protein which also transports LDL-C...
VLDL (being made of APO-b transports both trigs and cholesterol) Normally trigs are the biggest fraction..but if trigs are lowered by more than 50% in the VLDL protein packet..Then the VLDL is converted to LDL-C..So definitely a POSA at the time of Mori and Kura would have considered it obvious that trig lowering by any means, including EPA, would have to increase the LDL-C levels..And not what Du thinks..
To this day it remains a mystery of sorts as to why pure EPA alone can lower trigs and not increase harmful cholesterol..It is still not obvious.
My hypothesis is that this special effect of EPA is the result of EPA's special ability to lower Systemic Inflammation (SI). What is understood today is that trig levels reflect not so much dietary intake or liver production...But are regulated in a similar fashion to way blood sugar levels are...And that is by controlling the rate of removal. We are more familiar with the effects of insulin on controlling blood sugar..Insulin activity increases the removal of sugars (which are fuels like trigs) from the blood and stores them in the adipose tissue and we should not be surprised if trig use similar methods...The key here is that Systemic Inflammation (SI) elevation causes Insulin Resistance (IR) and IR weakens the ability of insulin to lower blood sugar and store it in the fat tissue. Triglyceries have their own brand of Insulin which is called Fatty Acid Synthase (FAS)..and its potency is like Insulin is diminished by high SI...
A plausable reason why EPA alone might be able to lower trigs and not raise LDL-C i due to the fact that EPA alone effects SI levels..This is not controversial..It is well known to scientists who study SI,,just not well known to cardiologists an lipidologists..EPA's effect might operate to remove trigs by FAS while other agents,,Fibrates, niacin, or DHA Which lacks the correct 3 dimmensional structure to interact with the eicosanoid cell membrane receptors that are the major controllers..of systemic Inflammation..EPA...By lowering SI could lower trigs the physiological way by increasing FAS activity and that might not increase LDL as much as the non physiological removals by other drugs..
If we, including epidemiologists, cardiologists and Diabetes specialists..recognized the similarities between trig control and diabetes..Then things might be understood a little better,,We should be thinking Trigabetes.
I do not envy Judge Du having to consider all these complicated issues in lipid and inflammatory and can understand why she came to the wrong conclusion..There is no way in 2000 or even ten years ago a POSA would have reached the conclusion that DU reached...
It would be like me that has a background in Chemical Engineering and clinical medicine could not possibly understand the nuances in a comple patent issue..
":>) JL
Recent AMRN News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM